Literature DB >> 2960613

In vivo studies on allotolerance perimetamorphically induced in control and thymectomized Xenopus.

J C Arnall1, J D Horton.   

Abstract

Implantation of either major histocompatibility complex (MHC)-disparate thymus to 7-day thymectomized (Tx) Xenopus in late larval life, or allogeneic skin to perimetamorphic controls, routinely induces tolerance towards implant-strain skin grafts applied in adult life. To characterize this allotolerance further, additional in vivo approaches were attempted. Injection of gamma-irradiated (5000 rads) implant-strain splenocytes into frogs bearing tolerant skin grafts revealed (within 3 days) significantly elevated tritiated thymidine uptake by host spleen cells, compared to siblings injected with isogeneic cells. Although this in vivo 'mixed leucocyte reaction' proved to be thymus dependent, the identity of the cells involved awaits clarification. When non-restored Tx Xenopus are injected with live MHC-disparate splenocytes, graft-versus-host (GVH)-induced mortality ensued within 2 weeks. Such GVH disease also occurred (albeit more chronically) when Tx allothymus-implanted animals were given MHC-incompatible splenocytes, but only when these came from the thymus donor strain. Splenocytes from thymus-implanted animals failed to achieve GVH-induced splenomegaly when transferred to appropriate hosts (bearing MHC antigens of the thymus donor strain). Overall, the experiments indicate that alloreactivity against donor cells is impaired but not completely inhibited in Xenopus following perimetamorphic implantation.

Entities:  

Mesh:

Year:  1987        PMID: 2960613      PMCID: PMC1453976     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  14 in total

1.  Graft versus host reactions. Their natural history, and applicability as tools of research.

Authors:  M SIMONSEN
Journal:  Prog Allergy       Date:  1962

2.  Lymphocytes which differentiate in an allogeneic thymus. I. Response to MLC determinants and skin grafts from the thymus donor strain.

Authors:  B Kindred
Journal:  Cell Immunol       Date:  1976-08       Impact factor: 4.868

3.  Anti-idiotypic T cells suppress rejection of renal allografts in rats.

Authors:  F Lancaster; Y L Chui; J R Batchelor
Journal:  Nature       Date:  1985 May 23-29       Impact factor: 49.962

4.  Immunological activity of transplanted spleens in Xenopus laevis.

Authors:  J C Clark; D R Newth
Journal:  Experientia       Date:  1972-08-15

5.  Response to skin allografts in Xenopus laevis following thymectomy at early stages of lymphoid organ maturation.

Authors:  J D Horton; M J Manning
Journal:  Transplantation       Date:  1972-08       Impact factor: 4.939

6.  Immune responses of thymus/lymphocyte embryonic chimeras: studies on tolerance and major histocompatibility complex restriction in Xenopus.

Authors:  M F Flajnik; L Du Pasquier; N Cohen
Journal:  Eur J Immunol       Date:  1985-06       Impact factor: 5.532

7.  Effector and regulator functions of splenic and thymic lymphocytes in the clawed toad Xenopus.

Authors:  E Hsu; M H Julius; L Du Pasquier
Journal:  Ann Immunol (Paris)       Date:  1983 Nov-Dec

8.  Allograft rejection in Xenopus laevis following larval thymectomy.

Authors:  C Kaye; R Tompkins
Journal:  Dev Comp Immunol       Date:  1983       Impact factor: 3.636

9.  Xenopus MHC class II molecules. I. Identification and structural characterization.

Authors:  J F Kaufman; M F Flajnik; L Du Pasquier; P Riegert
Journal:  J Immunol       Date:  1985-05       Impact factor: 5.422

10.  Specific in vivo and nonspecific in vitro alloreactivities of adult frogs (Xenopus laevis) that were thymectomized during early larval life.

Authors:  S Nagata; N Cohen
Journal:  Eur J Immunol       Date:  1983-07       Impact factor: 5.532

View more
  1 in total

Review 1.  Comparative and developmental study of the immune system in Xenopus.

Authors:  Jacques Robert; Yuko Ohta
Journal:  Dev Dyn       Date:  2009-06       Impact factor: 3.780

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.